Absci (ABSI) Intangibles (2021 - 2026)
Absci (ABSI) posted Intangibles of $40.8 million for Q1 2026, down 1.8% sequentially from $41.5 million in Q4 2025, and down 7.43% YoY from $44.0 million in Q1 2025.
Absci (ABSI) Intangibles (2021 - 2026) Analysis & Trends
Absci has reported Intangibles for 6 years, with the latest figure at $40.8 million in Q1 2026.
- Quarterly Intangibles fell 7.43% year-over-year to $40.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (down 7.43% YoY) and the FY2025 annual result came in at $41.5 million, down 7.51% from the prior year.
- Intangibles retreated to $40.8 million in Q1 2026 per ABSI's latest filing, from $41.5 million in the prior quarter.
- Over five years, Intangibles peaked at $53.3 million in Q2 2022 and troughed at $40.8 million in Q1 2026.
- A 5-year average of $47.3 million and a median of $47.4 million in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2025: Intangibles decreased 1.63% in 2023, then slipped 7.51% in 2025.
- Over 5 years, Intangibles stood at $51.6 million in 2022, then slipped by 6.53% to $48.3 million in 2023, then slipped by 6.98% to $44.9 million in 2024, then declined by 7.51% to $41.5 million in 2025, then retreated by 1.8% to $40.8 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $40.8 million, $41.5 million, and $42.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Absci | 1.58 Bn | 1.37 Bn | - | 40.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 40.05 Mn |
| Mar 31, 2026 | 40.77 Mn |
| Dec 31, 2025 | 41.51 Mn |
| Sep 30, 2025 | 42.36 Mn |
| Jun 30, 2025 | 43.20 Mn |
| Mar 31, 2025 | 44.04 Mn |
| Dec 31, 2024 | 44.88 Mn |
| Sep 30, 2024 | 45.73 Mn |
| Jun 30, 2024 | 46.57 Mn |
| Mar 31, 2024 | 47.41 Mn |
| Dec 31, 2023 | 48.25 Mn |
| Sep 30, 2023 | 49.10 Mn |
| Jun 30, 2023 | 49.94 Mn |
| Mar 31, 2023 | 50.78 Mn |
| Dec 31, 2022 | 51.62 Mn |
| Sep 30, 2022 | 52.47 Mn |
| Jun 30, 2022 | 53.31 Mn |
| Mar 31, 2022 | 51.62 Mn |
| Dec 31, 2021 | 54.99 Mn |
| Sep 30, 2021 | 55.84 Mn |